Top news from ACC 2019
Multiple studies based on phase 3 clinical trials of the investigational drug solriamfetol have found that it may be effective for improving next-day wakefulness and work productivity in people with narcolepsy and obstructive sleep apnea, and that the drug can maintain its effect throughout the day as well as for up to 6 months. Also today, ankylosing spondylitis progression slowed when NSAIDs were added to TNFi, chronic kidney disease more common among patients with type 2 diabetes, laws that promote drug price transparency gain ground. Listen to the MDedge Daily News for today’s top news.
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.